| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | n/a | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | n/a | n/a |
| Pr/Book | 5.5 |
| Latest | F'cast | |
|---|---|---|
| Revenue | n/a | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 30-Jun-21 | n/a | (1.72) | (2.30)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-22 | n/a | 2.58 | (3.20)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-23 | n/a | (4.03) | (4.70)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-24 | n/a | (4.60) | (4.20)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-25 | n/a | (3.06) | (2.40)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Notice of Results and Investor Presentation | 03-Mar-2026 | 07:00 | RNS |
| Restart of Phase 2-enabling toxicology programme | 17-Feb-2026 | 07:00 | RNS |
| Form 8.3 - Oxford Biomedica plc | 23-Jan-2026 | 16:36 | RNS |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 15.50p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 27.50 |
| 52 Week Low | 11.25 |
| Volume | 152,512 |
| Shares Issued | 138.07m |
| Market Cap | £21.40m |
| RiskGrade | 594 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 14:27 | 4,000 @ 15.20p |
| 14:21 | 25,000 @ 15.20p |
| 09:59 | 19,282 @ 15.60p |
| 09:47 | 639 @ 15.65p |
| 09:29 | 200 @ 15.20p |
You are here: research